Feasibility Analysis of p62 (SQSTM1)—Encoding DNA Vaccine as a Novel Cancer Immunotherapy

REFERENCES

• Sylvester RJ. Bacillus Calmette–Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011;18(2):113–120.
   Google Scholar
• Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer [10.1038/nrc3153]. 2011;11(11):805–812.
   PubMed Web of Science ®Google Scholar
• Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014;26(0):13–21.
   Google Scholar
• Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol 2014;26(0):78–88.
   Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 Nov;3(11):991–998.
   PubMed Web of Science ®Google Scholar
• Hunter P. Vaccines against cancer. EMBO Rep 2014 2014-05-01 00:00:00;15(5):485–488.
   Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008 Oct;9(10):776–788.
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8:108–120.
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013 Apr 1;2(4):e23803.
   PubMed Web of Science ®Google Scholar
• Ilyinskii PO, Meriin AB, Gabai VL, Zhirnov OP, Thoidis G, Shneider AM. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine 2008;26(18):2177–2185.
   Google Scholar
• Ilyinskii PO, Thoidis G, Sherman MY, Shneider A. Adjuvant potential of aggregate-forming polyglutamine domains. Vaccine 2008;26(26):3223–3226.
   Google Scholar
• Ilyinskii PO, Gambaryan AS, Meriin AB, Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency. PLoS One 2008;3(1):e1417.
   Google Scholar
• Ilyinskii PO, Thoidis G, Shneider AM. Development of a vaccine against pandemic influenza viruses: current status and perspectives. Int Rev Immunol 2008;27(6):392–426.
   Web of Science ®Google Scholar
• Ilyinskii PO, Schmidt T, Lukashev D, Importance of mRNA secondary structural elements for the expression of influenza virus genes. Omics 2009 Oct;13(5):421–430.
   Google Scholar
• Denies S, Sanders NN. Recent progress in canine tumor vaccination: potential applications for human tumor vaccines. Expert Rev Vaccines 2012;11(11):1375–1386.
   Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. [Review]. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009 September 1, 2009;15(17):5323–5337.
   Google Scholar
• Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol. [Review]. 2014;16(6):495–501.
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT, Wooten MW. Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 2007 Feb;32(2):95–100.
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009 Jun 12;137(6):1001–1004.
   PubMed Web of Science ®Google Scholar
• Puissant A, Fenouille N, Auberger P. When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res 2012;2(4):397–413.
   PubMed Web of Science ®Google Scholar
• Qiang L, Zhao B, Ming M, Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci 2014;111(25):9241–9246.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Durán A, Selloum M, Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 2006;3(3):211–222.
   PubMed Web of Science ®Google Scholar
• Kirkin V, Lamark T, Sou Y-S, A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol Cell 2009;33(4):505–516.
   PubMed Web of Science ®Google Scholar
• Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007;130(6):986–988.
   PubMed Web of Science ®Google Scholar
• Duran A, Linares JF, Galvez AS, The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008;13(4):343–354.
   PubMed Web of Science ®Google Scholar
• Ling J, Kang Ya, Zhao R, KrasG12D-induced IKK2/OI/NF-O€B activation by IL-1O± and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21(1):105–120.
   Google Scholar
• Sui X, Chen R, Wang Z, Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013;4:e838.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. The four faces of autophagy: Implications for cancer therapy. Cancer Res 2014;74(3):647–651.
   PubMed Web of Science ®Google Scholar
• Venanzi F, Shifrin V, Sherman MY, Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget 2013;4(10):1829–1835.
   Google Scholar
• Jain A, Lamark T, Sjøttem E, p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 2010;285(29):22576–22591.
   PubMed Web of Science ®Google Scholar
• Zhu K, Qin H, Cha SC, Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 2007;25(46):7955-7961.
   Google Scholar
• Guo K, Tang JP, Tan CP, Wang H, Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 2008;7(5):750–757.
   PubMed Web of Science ®Google Scholar
• Guo K, Li J, Tang JP, Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011;3(99):99ra85.
   PubMed Web of Science ®Google Scholar
• Dao T, Yan S, Veomett N, Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5(176):176ra33.
   PubMed Web of Science ®Google Scholar
• Hong CW, Zeng Q. Awaiting a new era of cancer immunotherapy. Cancer Res 2012;72(15):3715–3719.
   Google Scholar
• Hong CW, Zeng Q. Tapping the treasure of intracellular oncotargets with immunotherapy. FEBS Lett 2014;588(2):350–355.
   Google Scholar
• Guo K, Tang JP, Li J, Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice 2012;3(2):158–71.
   Google Scholar
• Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 2007;14(1):73–80.
   Google Scholar
• Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 2003;22(15):2322–2333.
   Google Scholar
• Gao C, Cao W, Bao L, Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol 2010;12(8):781–790.
   PubMed Web of Science ®Google Scholar
• Galavotti S, Bartesaghi S, Faccenda D, The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013;32(6):699–712.
   PubMed Web of Science ®Google Scholar
• Li L, Shen C, Nakamura E, SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 2013;24(6):738-750.
   Google Scholar
• Mathew R, Karp CM, Beaudoin B, Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137(6):1062–1075.
   PubMed Web of Science ®Google Scholar
• Inami Y, Waguri S, Sakamoto A, Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 2011;193(2):275–284.
   PubMed Web of Science ®Google Scholar
• Inoue D, Suzuki T, Mitsuishi Y, Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 2012;103(4):760–766.
   PubMed Web of Science ®Google Scholar
• Ellis RA, Horswell S, Ness T, Prognostic impact of p62 expression in cutaneous malignant melanoma. J Invest Dermatol 2014;134(5):1476–8.
   Google Scholar
• Hiruma Y, Honjo T, Jelinek DF, Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009;113(20):4894–4902.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Torigoe T, Asanuma H, Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology 2006;48(2):157–161.
   Google Scholar
• Giatromanolaki A, Sivridis E, Mendrinos S, Koutsopoulos AV, Koukourakis MI. Autophagy proteins in prostate cancer: Relation with anaerobic metabolism and Gleason score. Urol Oncol 2014;32(1):39.e11–39.e18.
   Google Scholar
• Chang MA, Morgado M, Warren CR, Hinton CV, Farach-Carson MC, Delk NA. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines. The Prostate 2014;74(2):149–163.
   Google Scholar